TIDMHIK
RNS Number : 7108F
Hikma Pharmaceuticals Plc
19 May 2017
Hikma Pharmaceuticals PLC
Voting Results of 2017 Annual General Meeting
LONDON, 19 May 2017 - Hikma Pharmaceuticals PLC (the "Company")
announces its Annual General Meeting ("AGM"), held at Sofitel St
James, 6 Waterloo Place, London SW1Y 4AN on 19 May 2017 commenced
at 10:00 am today. All resolutions were duly passed by shareholders
by way of a poll. Resolutions 1 to 19 were passed as ordinary
resolutions and Resolutions 20 to 23 were passed as special
resolutions.
As previously announced, Mr. Michael Ashton retired from the
Board at the close of the AGM.
Copies of the resolutions dealing with special business passed
at the AGM have been submitted to the UK Listing Authority for
publication through the Listing Authority's Document Viewing
Facility.
The total number of votes cast on the poll for each resolution
(the full text of the resolutions is detailed in the notice of the
AGM dated 7 April 2017) is set out below. The number of Ordinary
Shares in issue on 19 May 2017 was 240,380,475.
Resolution Votes % Votes % Withheld Total Cast
For Against
------------------------- ------------ -------- ----------- ------- ---------- ------------
1. To receive
the 2016 report
and accounts 197,423,759 99.84% 319,920 0.16% 6,643 197,750,322
------------------------- ------------ -------- ----------- ------- ---------- ------------
2. To approve
a final dividend
of 22 cents
per share 197,743,879 100.00% 0 0.00% 6,443 197,750,322
------------------------- ------------ -------- ----------- ------- ---------- ------------
3. To re-appoint
PricewaterhouseCoopers
LLP as auditors 197,741,251 100.00% 905 0.00% 8,166 197,750,322
------------------------- ------------ -------- ----------- ------- ---------- ------------
4.To authorise
the Audit Committee
to determine
the auditors'
remuneration 197,688,953 99.97% 53,203 0.03% 8,166 197,750,322
------------------------- ------------ -------- ----------- ------- ---------- ------------
5. To elect
Nina Henderson
as a director 197,534,627 99.89% 208,786 0.11% 6,854 197,750,267
------------------------- ------------ -------- ----------- ------- ---------- ------------
6. To re-elect
Said Darwazah
as a director 193,519,353 98.05% 3,848,526 1.95% 382,442 197,750,321
------------------------- ------------ -------- ----------- ------- ---------- ------------
7. To re-elect
Mazen Darwazah
as a director 195,813,592 99.21% 1,551,895 0.79% 384,835 197,750,322
------------------------- ------------ -------- ----------- ------- ---------- ------------
8. To re-elect
Robert Pickering
as a director 197,076,319 99.66% 667,559 0.34% 6,443 197,750,321
------------------------- ------------ -------- ----------- ------- ---------- ------------
9.To re-elect
Ali Al-Husry
as a director 196,769,085 99.57% 857,947 0.43% 123,290 197,750,322
------------------------- ------------ -------- ----------- ------- ---------- ------------
10. To re-elect
Dr. Ronald
Goode as a
director 195,703,815 98.97% 2,039,923 1.03% 6,584 197,750,322
------------------------- ------------ -------- ----------- ------- ---------- ------------
11. To re-elect
Patrick Butler
as a director 197,506,890 99.88% 236,848 0.12% 6,584 197,750,322
------------------------- ------------ -------- ----------- ------- ---------- ------------
12. To re-elect
Dr. Jochen
Gann as a director 196,795,912 99.58% 830,979 0.42% 123,431 197,750,322
------------------------- ------------ -------- ----------- ------- ---------- ------------
13. To re-elect
John Castellani
as a director 197,586,602 99.92% 157,277 0.08% 6,443 197,750,322
------------------------- ------------ -------- ----------- ------- ---------- ------------
14. To re-elect
Dr. Pamela
Kirby as a
director 195,665,777 98.96% 2,053,602 1.04% 6,468 197,725,847
------------------------- ------------ -------- ----------- ------- ---------- ------------
15. To approve
the directors'
remuneration
policy 169,053,856 86.39% 26,622,257 13.61% 2,074,207 197,750,320
------------------------- ------------ -------- ----------- ------- ---------- ------------
16. To approve
the remuneration
report for
the year ended
31 December
2016 193,651,599 97.93% 4,091,754 2.07% 6,968 197,750,321
------------------------- ------------ -------- ----------- ------- ---------- ------------
17. To approve
the extension
of the effective
period of the
Executive Incentive
Plan 170,276,525 86.12% 27,450,966 13.88% 22,830 197,750,321
------------------------- ------------ -------- ----------- ------- ---------- ------------
18. To approve
the increase
of the aggregate
directors'
fee limit 197,640,307 99.98% 45,091 0.02% 64,924 197,750,322
------------------------- ------------ -------- ----------- ------- ---------- ------------
19. Authority
to allot shares 170,146,304 86.21% 27,221,034 13.79% 382,984 197,750,322
------------------------- ------------ -------- ----------- ------- ---------- ------------
20. To dis-apply
pre-emption
rights for
general purposes 196,872,145 99.56% 869,023 0.44% 9,154 197,750,322
------------------------- ------------ -------- ----------- ------- ---------- ------------
21. To dis-apply
pre-emption
rights for
an acquisition
or other capital
investment 173,591,716 87.79% 24,149,939 12.21% 8,666 197,750,321
------------------------- ------------ -------- ----------- ------- ---------- ------------
22. To authorise
the Company
to purchase
its own shares 197,014,413 99.66% 676,265 0.34% 59,643 197,750,321
------------------------- ------------ -------- ----------- ------- ---------- ------------
23. To authorise
the Company
to hold general
meetings on
no less than
14 clear days'
notice 187,053,655 94.82% 10,213,802 5.18% 482,864 197,750,321
------------------------- ------------ -------- ----------- ------- ---------- ------------
Declaration of final dividend
The dividend of 22 cents per share will be paid on 25 May 2017
to shareholders on the register on 7 April 2017. Shareholders who
are not resident in Jordan have been given the option of receiving
their dividend in Pounds Sterling. The exchange rate in respect of
this dividend will be $1.2898 to GBP1. The exchange rate for
Jordanian Dinar is fixed to the US Dollar at circa 1JD to
$1.41.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary +44 20 7399 2670
Susan Ringdal
VP for Investor Relations and
Strategy +44 20 7399 2670
About Hikma
Hikma Pharmaceuticals PLC is a fast-growing multinational group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma operates through three businesses: "Injectables", "Branded"
and "Generics", based principally in the United States, the Middle
East and North Africa ("MENA") and Europe. In 2016, Hikma achieved
revenue of $1,950 million and profit attributable to shareholders
of $155 million. In the United States, Hikma operates through its
wholly owned subsidiary, West-Ward Pharmaceuticals Corp., with
operations based in New Jersey, Ohio and Tennessee. For more
information visit www.hikma.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGSFEFDUFWSELI
(END) Dow Jones Newswires
May 19, 2017 09:44 ET (13:44 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Apr 2024 to May 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From May 2023 to May 2024